Table 3.
Finland | England | Canada | USA | |
---|---|---|---|---|
Importance | +++ | ++ | +++ | +++ |
Main basis | Research law; EU | Health ministry + NHS regulation; EU | Requirement from research funder CIHR | Research law; health ministry regulation |
Area responsibility | Yes | No, inclusive | No, selective | No |
Number | Few, law defined | Declining, NRES defined | Many, free | Many, free |
Private RECs | No | Few | Yes | Yes, important |
All clinical research in the main system | Yes | Not research outside NHS | Not research outside health care units | Yes |
Appointing body | Hospital district | NRES | Hospital board b | Hospital b/private |
Funding | Fees + hospital district | NHS | Fees + hospital b/grants | Hospital b/fees (private) |
REC control body | No | Yes, strong NRES | No | Yes, OHRP + FDA |
0/+ provides a subjective estimate of the importance of the issue, on relative terms within the four countries; 0, no or little activity. CIHR, Canadian Institutes of Health Research; EU, EU Clinical trials directive; FDA, Food and Drug Administration; NRES, National Research Ethics Service; NHS, National Health Service; OHRP, Office of Human Research Protection.
a Within the main health care system; two systems in the USA.
b Hospital or other health care unit.